[
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call",
    "summary": "Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing pressure from generic competition in legacy products. Management attributed the quarter’s performance to robust uptake in key drugs such as Breyanzi, Reblozyl, and Camzyos, as well as the initial traction from recent launches like Cobenfi and OpdivoCuvanti. CEO Christopher Boerner noted that, despite challenges from generic entries and Medicare Part D changes affecting old",
    "url": "https://finnhub.io/api/news?id=b590a1dbbbe5eb7cc82dfd90174d5022517ccfdc01b55ca37d85d32ac22067bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750442981,
      "headline": "The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call",
      "id": 135456140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing pressure from generic competition in legacy products. Management attributed the quarter’s performance to robust uptake in key drugs such as Breyanzi, Reblozyl, and Camzyos, as well as the initial traction from recent launches like Cobenfi and OpdivoCuvanti. CEO Christopher Boerner noted that, despite challenges from generic entries and Medicare Part D changes affecting old",
      "url": "https://finnhub.io/api/news?id=b590a1dbbbe5eb7cc82dfd90174d5022517ccfdc01b55ca37d85d32ac22067bb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?",
    "summary": "Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.",
    "url": "https://finnhub.io/api/news?id=b46854599b3c289f46af7ea3da087a54549effccc363f2b7aba2aae7a7b5432a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750428060,
      "headline": "Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?",
      "id": 135440911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.",
      "url": "https://finnhub.io/api/news?id=b46854599b3c289f46af7ea3da087a54549effccc363f2b7aba2aae7a7b5432a"
    }
  },
  {
    "ts": null,
    "headline": "I'm Buying Dividend Giants At Huge Discounts",
    "summary": "I'm Buying Dividend Giants At Huge Discounts",
    "url": "https://finnhub.io/api/news?id=c4e55e0c5d02211dda3cc076c7a0eb04974633f7f0e66792fdfe7e6012c11cbb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750410000,
      "headline": "I'm Buying Dividend Giants At Huge Discounts",
      "id": 135425473,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c4e55e0c5d02211dda3cc076c7a0eb04974633f7f0e66792fdfe7e6012c11cbb"
    }
  }
]